Publication|Videos|July 18, 2024
PurpleLab Accelerates Clinical Trial Lifecycle with Real-World-Data
Author(s)PurpleLab
Jason Gagner (Vice President of Product for Life Science, PurpleLab) talks about clinical trial variables and how PurpleLab is working to maintain patient retention and accelerate site feasibility.
Approximately 80% of clinical trials will face delays at some point in the trial process. Jason Gagner talked with ACT about how PurpleLab uses real-world data to better inform trials and improve their success rates.
Learn More About:
- Utilizing real-world data (RWD) to assist clinical trials achieve key milestones
- Employing a criteria specific geographic analysis of patient populations to expedite site feasibility assessments
- Understanding the impact of diversity, equity, and inclusion (DEI) in clinical trials on meeting trial objectives and timelines
- Integrating social determinants of health (SDOH) data to minimize patient dropout rates
Related Content
Trending on Applied Clinical Trials Online
1
The CRA of the Future: From Monitoring Activity to Strategic Site Partnership
2
ACT Brief: Data Standardization Bottleneck in Real-Time Monitoring, US Biotech FIH Trial Regulatory Frustration, and FDA Approval of Zenbexus for Multiple Myeloma
3
Closing the Dead Time Gap in Clinical Data: Q&A with Raviv Pryluk, PhaseV
4
ACT Brief: Data Quality as Foundational to Trial Modernization, CRAs Evolving to Strategic Site Partners, and 2026 Emerging Pharma Leaders Announced
5